Helus Pharma Appoints Industry Veteran Dr. Freda Lewis-Hall to Board

Helus Pharma, the commercial operating name of Cybin Inc., has made a significant strategic move by appointing Dr. Freda Lewis-Hall to its board of directors, where she will also chair the company's Scientific Advisory Committee, pending approval by Cboe Canada. Dr. Lewis-Hall brings over four decades of experience in clinical care, research, academia, and senior biopharmaceutical leadership, including more than a decade on Pfizer's executive leadership team as executive vice president and chief medical officer, along with leadership roles at Vertex Pharmaceuticals, Bristol Myers Squibb, Pharmacia Corporation, and Eli Lilly and Company. As a Distinguished Fellow of the American Psychiatric Association and former advisor to the National Institute of Mental Health, she will provide crucial scientific, clinical, and regulatory governance across Helus Pharma's portfolio as the company advances its novel serotonergic agonist (NSA) programs targeting serious mental health conditions.

Helus Pharma is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

This news was disseminated on behalf of Helus Pharma and may include paid advertising. For more details, readers can view the full press release via the provided hyperlink. The company operates in Canada, the United States, the United Kingdom, and Ireland, and updates can be found by visiting their website or following them on social media platforms like X, LinkedIn, YouTube, and Instagram. This announcement highlights Helus Pharma's commitment to advancing mental health treatments through experienced leadership and innovative drug development, positioning it as a key player in the biopharmaceutical industry focused on addressing critical healthcare challenges.